Notice of Effectiveness · EFFECT
newcleo plc
NWCLNASDAQEQUITYCurrent
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-10-16
- Effective time (as filed)
- 16:00:00
- Form
- F-1
Registrant 1
- Registrant
- newcleo plc
- Registrant CIK
- 0002131813
- File number
- 333-299328
Company context
new cleo is an innovative nuclear energy company developing AMRs cooled by liquid lead, and facilities to produce nuclear fuel from recycled nuclear waste, with the goal of delivering abundant, competitive, low-carbon energy. The company was founded by physicist-entrepreneur Stefano Buono following the USD $3.9 billion sale of his previous venture - Nasdaq-listed nuclear medicine company Advanced Accelerator Applications - to Novartis. With, approximately USD $780 million in private funding, and more than 900 highly skilled employees across Europe and the United States, the company has built a network of over 100 industry partnerships and supports its growth through the targeted acquisition and vertical integration of key companies in the nuclear supply chain.